FI111254B - Menetelmä terapeuttisesti käyttökelpoisten substituoitujen pyratsoliyhdisteiden valmistamiseksi - Google Patents

Menetelmä terapeuttisesti käyttökelpoisten substituoitujen pyratsoliyhdisteiden valmistamiseksi Download PDF

Info

Publication number
FI111254B
FI111254B FI935672A FI935672A FI111254B FI 111254 B FI111254 B FI 111254B FI 935672 A FI935672 A FI 935672A FI 935672 A FI935672 A FI 935672A FI 111254 B FI111254 B FI 111254B
Authority
FI
Finland
Prior art keywords
process according
formula
ylmethyl
compound
pyrazol
Prior art date
Application number
FI935672A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI935672A (fi
FI935672A0 (fi
Inventor
Gene Michael Bright
Jr Willard Mckowan Welch
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of FI935672A0 publication Critical patent/FI935672A0/fi
Publication of FI935672A publication Critical patent/FI935672A/fi
Application granted granted Critical
Publication of FI111254B publication Critical patent/FI111254B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Reproductive Health (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FI935672A 1992-12-17 1993-12-16 Menetelmä terapeuttisesti käyttökelpoisten substituoitujen pyratsoliyhdisteiden valmistamiseksi FI111254B (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99222892A 1992-12-17 1992-12-17
US99222892 1992-12-17

Publications (3)

Publication Number Publication Date
FI935672A0 FI935672A0 (fi) 1993-12-16
FI935672A FI935672A (fi) 1994-06-18
FI111254B true FI111254B (fi) 2003-06-30

Family

ID=25538068

Family Applications (1)

Application Number Title Priority Date Filing Date
FI935672A FI111254B (fi) 1992-12-17 1993-12-16 Menetelmä terapeuttisesti käyttökelpoisten substituoitujen pyratsoliyhdisteiden valmistamiseksi

Country Status (26)

Country Link
EP (2) EP0674631B1 (de)
JP (1) JP2781661B2 (de)
KR (1) KR100190730B1 (de)
CN (1) CN1045293C (de)
AT (1) ATE187451T1 (de)
AU (1) AU690079B2 (de)
BR (1) BR9307664A (de)
CA (1) CA2150703C (de)
CZ (1) CZ287925B6 (de)
DE (1) DE69327254T2 (de)
DK (1) DK0674631T3 (de)
EG (1) EG20440A (de)
ES (1) ES2139676T3 (de)
FI (1) FI111254B (de)
GR (1) GR3032461T3 (de)
HU (1) HUT65822A (de)
IL (1) IL107947A (de)
MY (1) MY109522A (de)
NO (1) NO307884B1 (de)
NZ (1) NZ256620A (de)
PL (1) PL175982B1 (de)
PT (1) PT674631E (de)
RU (1) RU2130453C1 (de)
TW (1) TW237455B (de)
WO (1) WO1994013661A1 (de)
ZA (1) ZA939406B (de)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9222253D0 (en) * 1992-10-23 1992-12-09 Celltech Ltd Chemical compounds
GB9304919D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
GB9304920D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
AU692484B2 (en) * 1993-10-12 1998-06-11 Du Pont Pharmaceuticals Company 1N-alkyl-N-arylpyrimidinamines and derivatives thereof
ATE260911T1 (de) * 1993-12-22 2004-03-15 Celltech R&D Ltd Trisubstituierte phenyl-derivate, verfahren zu deren herstellung und deren verwendung als phosphodiesterase (typ iv) hemmstoffe
GB9326600D0 (en) * 1993-12-22 1994-03-02 Celltech Ltd Chemical compounds
KR100263429B1 (ko) * 1994-06-06 2000-08-01 디. 제이. 우드 코르티코트로핀-방출 인자(crf) 길항 활성을 갖는 치환된 피라졸
AU719558B2 (en) * 1994-06-06 2000-05-11 Pfizer Inc. Substituted pyrazoles having corticotropin-releasing factor (CRF) antagonist activity
US6245774B1 (en) 1994-06-21 2001-06-12 Celltech Therapeutics Limited Tri-substituted phenyl or pyridine derivatives
US5786354A (en) * 1994-06-21 1998-07-28 Celltech Therapeutics, Limited Tri-substituted phenyl derivatives and processes for their preparation
GB9412573D0 (en) 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
GB9412571D0 (en) 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
US7067664B1 (en) 1995-06-06 2006-06-27 Pfizer Inc. Corticotropin releasing factor antagonists
US6403599B1 (en) 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
GB9526246D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9526245D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9608435D0 (en) * 1996-04-24 1996-06-26 Celltech Therapeutics Ltd Chemical compounds
US6011052A (en) * 1996-04-30 2000-01-04 Warner-Lambert Company Pyrazolone derivatives as MCP-1 antagonists
US6191131B1 (en) 1997-07-23 2001-02-20 Dupont Pharmaceuticals Company Azolo triazines and pyrimidines
US6313124B1 (en) 1997-07-23 2001-11-06 Dupont Pharmaceuticals Company Tetrazine bicyclic compounds
US6124289A (en) * 1996-07-24 2000-09-26 Dupont Pharmaceuticals Co. Azolo triazines and pyrimidines
US6060478A (en) * 1996-07-24 2000-05-09 Dupont Pharmaceuticals Azolo triazines and pyrimidines
US7094782B1 (en) 1996-07-24 2006-08-22 Bristol-Myers Squibb Company Azolo triazines and pyrimidines
US5861398A (en) * 1996-08-26 1999-01-19 Alanex Corporation Benzoperimidine-carboxylic acids and derivatives thereof
WO1998011075A1 (en) 1996-09-16 1998-03-19 Du Pont Pharmaceuticals Company Pyrazinones and triazinones and their derivatives thereof
GB9619284D0 (en) * 1996-09-16 1996-10-30 Celltech Therapeutics Ltd Chemical compounds
GB9622363D0 (en) 1996-10-28 1997-01-08 Celltech Therapeutics Ltd Chemical compounds
US5760225A (en) * 1996-11-15 1998-06-02 Neurogen Corporation Certain pyrazole derivatives as corticotropin-releasing factor receptor CRF1 specific ligands
GB9625184D0 (en) * 1996-12-04 1997-01-22 Celltech Therapeutics Ltd Chemical compounds
JP2001507349A (ja) 1996-12-23 2001-06-05 セルテック セラピューティックス リミテッド 縮合多環式２−アミノピリミジン誘導体、それらの製造およびたんぱく質チロシンキナーゼ抑制因子としてのそれらの使用
US5723608A (en) * 1996-12-31 1998-03-03 Neurogen Corporation 3-aryl substituted pyrazolo 4,3-d!pyrimidine derivatives; corticotropin-releasing factor receptor (CRF1) specific ligands
GB9705361D0 (en) * 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
CN1142931C (zh) * 1997-03-26 2004-03-24 大正制药株式会社 4-四氢吡啶基嘧啶衍生物
GB9713087D0 (en) * 1997-06-20 1997-08-27 Celltech Therapeutics Ltd Chemical compounds
US5955471A (en) * 1998-01-13 1999-09-21 Sk Corporation Tetrahydroisoquinolinealkanol derivatives and pharmaceutical compositions containing same
AU3375999A (en) 1998-04-02 1999-10-25 Neurogen Corporation Aminoalkyl substituted 5,6,7,8-tetrahydro-9h pyrimidino(2,3-b)indole and 5,6,7,8-tetrahydro-9h-pyrimidino(4,5-b)indole derivatives: crf1 specific ligands
US6472402B1 (en) 1998-04-02 2002-10-29 Neurogen Corporation Aminoalkyl substituted 5,6,7,8-Tetrahydro-9H-Pyridino [2,3-B]indole derivatives
IL142893A0 (en) 1998-11-12 2002-04-21 Neurocrine Biosciences Inc Fused polyclic heterocyclic compounds and pharmaceutical compositions containing the same
DE69908173T2 (de) 1998-11-12 2004-08-19 Neurocrine Biosciences, Inc., San Diego Crf rezeptor-antagonisten und darauf bezogene methoden
US6531475B1 (en) 1998-11-12 2003-03-11 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods relating thereto
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
US6506784B1 (en) 1999-07-01 2003-01-14 3-Dimensional Pharmaceuticals, Inc. Use of 1,3-substituted pyrazol-5-yl sulfonates as pesticides
US6409988B1 (en) 1999-07-01 2002-06-25 3-Dimensional Pharmaceuticals, Inc. Radiolabeled 1-aryl pyrazoles, the synthesis thereof and the use thereof as pest GABA receptor ligands
AU6116800A (en) * 1999-07-22 2001-02-13 3-Dimensional Pharmaceuticals, Inc. 1-aryl-3-thioalkyl pyrazoles, the synthesis thereof and the use thereof as insecticides
WO2001025241A2 (en) 1999-10-06 2001-04-12 3-Dimensional Pharmaceuticals, Inc. Fused 1-(2,6-dichloro-4-trifluoromethylphenyl)-pyrazoles, the synthesis thereof and the use thereof as pesticides
GB9924862D0 (en) 1999-10-20 1999-12-22 Celltech Therapeutics Ltd Chemical compounds
TWI271406B (en) 1999-12-13 2007-01-21 Eisai Co Ltd Tricyclic condensed heterocyclic compounds, preparation method of the same and pharmaceuticals comprising the same
US6569885B1 (en) * 1999-12-23 2003-05-27 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
EP1293213A1 (de) * 2000-02-14 2003-03-19 Japan Tobacco Inc. Prophylactische/therapeutische agentia zur behandlung von postchirurgischen stress
AU2001234180A1 (en) * 2000-02-25 2001-09-03 Japan Tobacco Inc. Benzamide derivative and use thereof
GB0016453D0 (en) * 2000-07-04 2000-08-23 Hoffmann La Roche Pyrrole derivatives
GB0016787D0 (en) 2000-07-07 2000-08-30 Pfizer Ltd Compounds useful in therapy
US20060223824A1 (en) 2000-11-28 2006-10-05 Wyeth Serotonergic agents
US20060287335A1 (en) 2000-11-28 2006-12-21 Wyeth Serotonergic agents for treating sexual dysfunction
TWI312347B (en) 2001-02-08 2009-07-21 Eisai R&D Man Co Ltd Bicyclic nitrogen-containing condensed ring compounds
MXPA03009738A (es) 2001-04-27 2004-01-29 Eisai Co Ltd Pirazol [1,5-a] piridinas y medicinas que las contienen.
IL159120A0 (en) 2001-05-29 2004-05-12 Schering Ag Cdk inhibiting pyrimidines, production thereof and their use as medicaments
IL144900A (en) 2001-08-14 2013-12-31 Neurim Pharma 1991 Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs
US6638981B2 (en) 2001-08-17 2003-10-28 Epicept Corporation Topical compositions and methods for treating pain
DK1441724T3 (da) * 2001-09-27 2007-12-03 Serono Lab Fremgangsmåde til forögelse af endogene testosteronniveauer
US7176216B2 (en) 2002-10-22 2007-02-13 Eisai Co., Ltd. 7-phenylpyrazolopyridine compounds
DE60326869D1 (de) 2002-10-22 2009-05-07 Eisai R&D Man Co Ltd 7-phenylpyrazolopyridinverbindungen
WO2004041210A2 (en) 2002-11-05 2004-05-21 Smithkline Beecham Corporation Antibacterial agents
PL377520A1 (pl) 2002-12-13 2006-02-06 Warner-Lambert Company Llc Pochodne pregabaliny przeznaczone do leczenia fibromialgii i innych zaburzeń
US7160888B2 (en) 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
TW200800959A (en) 2005-06-10 2008-01-01 Wyeth Corp Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor
AU2006327317B2 (en) * 2005-12-23 2010-11-25 Astrazeneca Ab GABA-B receptor modulators
CL2008000119A1 (es) 2007-01-16 2008-05-16 Wyeth Corp Compuestos derivados de pirazol, antagonistas del receptor nicotinico de acetilcolina; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como demencia senil, alzheimer y esquizofrenia.
DE602008002600D1 (de) 2007-06-15 2010-10-28 Irm Llc Verbindungen und zusammensetzungen als itpkb-inhibitoren
WO2009104080A2 (en) 2008-02-20 2009-08-27 Targia Pharmaceuticals Cns pharmaceutical compositions and methods of use
CN102007133B (zh) 2008-04-15 2013-06-12 卫材R&D管理有限公司 3-苯基吡唑并[5,1-b]噻唑化合物
EP2291181B9 (de) 2008-04-18 2013-09-11 University College Dublin National University Of Ireland, Dublin Captodiamine zur Behandlung von depressionartigen Symptomen
AR078521A1 (es) 2009-10-08 2011-11-16 Eisai R&D Man Co Ltd Compuesto pirazolotiazol
DE102013002393A1 (de) 2013-02-13 2014-08-14 Rauch Landmaschinenfabrik Gmbh Verfahren zur Regelung des Massenstromes an Streugut bei einem Scheibenstreuer
CN114716389A (zh) * 2021-12-31 2022-07-08 北京岳达生物科技有限公司 一种3,5-二乙基异恶唑-4-羧酸的合成方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5063245A (en) * 1990-03-28 1991-11-05 Nova Pharmaceutical Corporation Corticotropin-releasing factor antagonism compounds

Also Published As

Publication number Publication date
HUT65822A (en) 1994-07-28
EP0959074A3 (de) 2000-06-07
NO307884B1 (no) 2000-06-13
BR9307664A (pt) 1999-06-29
ZA939406B (en) 1995-06-15
NO952397L (no) 1995-08-14
ATE187451T1 (de) 1999-12-15
ES2139676T3 (es) 2000-02-16
EG20440A (en) 1999-04-29
CA2150703A1 (en) 1994-06-23
DE69327254D1 (de) 2000-01-13
CN1093363A (zh) 1994-10-12
IL107947A0 (en) 1994-04-12
DE69327254T2 (de) 2000-03-30
WO1994013661A1 (en) 1994-06-23
PL309355A1 (en) 1995-10-02
GR3032461T3 (en) 2000-05-31
FI935672A (fi) 1994-06-18
EP0674631A1 (de) 1995-10-04
KR950704299A (ko) 1995-11-17
EP0959074A2 (de) 1999-11-24
TW237455B (de) 1995-01-01
KR100190730B1 (ko) 1999-06-01
AU5141393A (en) 1994-07-04
PT674631E (pt) 2000-04-28
JP2781661B2 (ja) 1998-07-30
NO952397D0 (no) 1995-06-16
DK0674631T3 (da) 2000-04-10
IL107947A (en) 1998-08-16
MY109522A (en) 1997-02-28
CN1045293C (zh) 1999-09-29
FI935672A0 (fi) 1993-12-16
EP0674631B1 (de) 1999-12-08
NZ256620A (en) 1996-05-28
AU690079B2 (en) 1998-04-23
CA2150703C (en) 2002-01-08
RU2130453C1 (ru) 1999-05-20
PL175982B1 (pl) 1999-03-31
CZ287925B6 (cs) 2001-03-14
JPH08500121A (ja) 1996-01-09
CZ158295A3 (en) 1995-12-13

Similar Documents

Publication Publication Date Title
FI111254B (fi) Menetelmä terapeuttisesti käyttökelpoisten substituoitujen pyratsoliyhdisteiden valmistamiseksi
FI112228B (fi) Menetelmä terapeuttisesti käyttökelpoisen aminosubstituoidun pyratsolin valmistamiseksi ja välituote
US5011931A (en) Process for the preparation of 1-methyl-3-methylthio-4-quinolone and the sulfinyl, and sulfonyl analogs thereof
EP0764153A1 (de) Substituierte pyrazole mit "corticotropin-releasing factor"-(crf) antagonistischer aktivität
US4980365A (en) N-substituted-5,6-dimethoxy-1,2-benzisoxazole-3-propanamine and related compounds as analgesic and hypotensive agents
FI91634B (fi) Menetelmä terapeuttisesti käyttökelpoisten 1,4-dihydropyridiinijohdannaisten valmistamiseksi
US5705646A (en) Substituted pyrazoles as CRF antagonists
US6838476B1 (en) Imidazoles with anti-inflammatory activity
JP2707936B2 (ja) β−オキソ−β−ベンゼンプロパンチオアミド誘導体
HU209293B (en) Process for producing cyclic substituted (quinolin-2-yl-methoxy)-phenyl acetic acid derivatives and pharmaceutical compositions containing them
JPH0473432B2 (de)
US5008264A (en) N-substituted-5,6-dimethoxy-1,2-benzisoxazole-3-propanamine and related compounds as analgesic and hypotensive agents
US5030639A (en) N-substituted-5,6-dimethoxy-1,2-benzisoxazole-3-propanamine and related compounds as analgesic and hypotensive agents
US5134151A (en) 2-picolylamine derivatives
US4997843A (en) 2,4-disubstituted derivatives of tetrahydrofuran useful for the treatment of PAF mediated illnesses
FI84717B (fi) Foerfarande foer framstaellning av ett terapeutiskt aktivt 1,3-oxatianderivat.
EP0230622A1 (de) 6H-Isoxazolo[5,4-d]pyrazolo[3,4-b]pyridine, Verfahren und Zwischenprodukte zu ihrer Herstellung und ihre Anwendung als Arzneimittel
CA2313302C (fr) Nouveaux inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US4927970A (en) Substituted 3-cyclobutene-1,2-dione intermediates
FI90866C (fi) Menetelmä lääkeaineina käyttökelpoisten 4-/2-(imidatsol-1-yyli)etyylitio/bentsoehappojohdannaisten valmistamiseksi
US4727156A (en) 3-(Substituted phenyl)-3-(1H-imidazol-1-ylmethyl)-2-methyl-5-{[(substituted phenyl)thio]me}isoxazolidine derivatives
EP0367888A1 (de) 2,2-Disubstituierte 2,3-Dihydro-1,4-benzodioxin-Derivate mit Blutdruck senkender Wirkung
JPH02311479A (ja) キノリン誘導体

Legal Events

Date Code Title Description
MA Patent expired